A phase II, open-label, multicenter study of nelmastobart in combination with docetaxel in patients with relapsed NSCLC expressing BTN1A1

Enhances Osimertinib Antitumor Activity in an EGFR-Mutant NSCLC (NCI-H1975) 3D Spheroid Model

Cell DIVE profiling of BTN1A1-associated spatial TME phenotypes in refractory CRC

Nelmastobart enhances immune-mediated tumor-killing activity when combined with cisplatin-pemetrexed therapy and osimertinib-based chemotherapy

Nelmastobart plus docetaxel in advanced NSCLC: initial safety and efficacy from a single-arm phase 2 study (STCUBE-004; NCT07306624)

Development and Validation of an Immunohistochemistry Scoring Method for BTN1A1 Expression in NSCLC

BTN1A1 Expression and Spatial Immune Profiling as Predictive Biomarkers for Nelmastobart in NSCLC

Multiplexed Immunohistochemistry (mIHC) Analysis and Clinical Outcomes of Nelmastobart in Combination with Trifluridine/Tipiracil and Bevacizumab in Patients with Refractory Colorectal Cancer (Phase 1b/2)

BTN1A1 blockade with Nelmastobart potentiates cisplatin-induced tumor suppression in NSCLC

Biomarkers of Nelmastobart efficacy: BTN1A1 expression and tumor microenvironment dynamics in colorectal cancer